

**Wednesday 19 August 2009**

### **CHANGE OF DIRECTORS' INTERESTS**

Australian health care company Prima BioMed (Prima) (ASX: PRR) is pleased to announce that the Directors have transferred a fraction of their listed PRRO options to Patersons Securities.

Patersons Securities have exercised these options for a total exercise price of \$321,429 and these funds will be used for the ongoing commercialization of the **CVac™** ovarian cancer therapy vaccine with the US FDA.

The directors intend to hold their remaining equity for a further 3 years.

Directors Appendix 3Y's are attached.

#### **About Prima BioMed**

Prima BioMed is an ASX listed Australian health care company. The Company is focused on technologies in the fields of cancer immunotherapy and immunology. Prima's lead product is the **CVac™** ovarian cancer vaccine therapy treatment. It has completed two successful clinical trials and is in the final stages of US FDA approval and eventual commercialisation.

The Company's broader, long term goal is to develop commercial cancer treatment technologies and programs for global markets.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of Entity:</b>	PRIMA BIOMED LIMITED (ASX: PRR)
<b>ABN:</b>	90 009 237 889

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director:</b>	MR. ATA GOKYILDIRIM
<b>Date of Last Notice:</b>	11 <sup>th</sup> August 2009

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or Indirect Interest</b>	Indirect														
<b>Nature of Indirect Interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Director Related Entity														
<b>Date of change</b>	12 <sup>th</sup> August 2009														
<b>No. of securities held prior to change</b>	<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 30%;"></th> <th style="width: 35%; text-align: center;">Shares</th> <th style="width: 35%; text-align: center;">Options</th> </tr> </thead> <tbody> <tr> <td style="background-color: #e0e0e0;"><b>Direct</b></td> <td style="text-align: center;">-</td> <td style="text-align: center;">-</td> </tr> <tr> <td style="background-color: #e0e0e0;"><b>Indirect</b></td> <td style="text-align: center;">234,000</td> <td style="text-align: center;">31,500,000</td> </tr> <tr> <td style="background-color: #e0e0e0;"><b>Total</b></td> <td style="text-align: center;"><b>234,000</b></td> <td style="text-align: center;"><b>31,500,000</b></td> </tr> </tbody> </table>				Shares	Options	<b>Direct</b>	-	-	<b>Indirect</b>	234,000	31,500,000	<b>Total</b>	<b>234,000</b>	<b>31,500,000</b>
	Shares	Options													
<b>Direct</b>	-	-													
<b>Indirect</b>	234,000	31,500,000													
<b>Total</b>	<b>234,000</b>	<b>31,500,000</b>													
<b>Class</b>	Listed Options exercisable at \$0.02 on or before 31 December 2011 (PRRO)														

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Number Acquired</b>		<b>Shares</b>	<b>Options</b>
	<b>Direct</b>	-	-
	<b>Indirect</b>	-	-
	<b>Total</b>	-	-
<b>Number Disposed</b>		<b>Shares</b>	<b>Options</b>
	<b>Direct</b>	-	-
	<b>Indirect</b>	-	8,035,715
	<b>Total</b>	-	<b>8,035,715</b>
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$0.042 per option		
<b>No. of Securities Held After Change</b>		<b>Shares</b>	<b>Options</b>
	<b>Direct</b>	-	-
	<b>Indirect</b>	234,000	23,464,285
	<b>Total</b>	<b>234,000</b>	<b>23,464,285</b>
<b>Nature of Change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Off-Market Transfer		

**Part 2 – Change of Director's Interests in Contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of Contract</b>	
<b>Nature of Interest</b>	
<b>Name of Registered Holder (if issued securities)</b>	
<b>Date of Change</b>	
<b>No. and Class of Securities to Which Interest Related Prior to Change</b>	
<small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest Acquired</b>	
<b>Interest Disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest After Change</b>	

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of Entity:</b>	PRIMA BIOMED LIMITED (ASX: PRR)
<b>ABN:</b>	90 009 237 889

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director:</b>	MR. MARTIN ROGERS
<b>Date of Last Notice:</b>	11 August 2009

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or Indirect Interest</b>	Indirect		
<b>Nature of Indirect Interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Director related entity		
<b>Date of change</b>	12 August 2009		
<b>No. of securities held prior to change</b>		Shares	Options
	Direct	-	-
	Indirect	497,500	38,000,000
	<b>Total</b>	<b>497,500</b>	<b>38,000,000</b>
<b>Class</b>	Listed Options exercisable at \$0.02 on or before 31 December 2011 (PRRO)		
<b>Number Acquired</b>		Shares	Options
	Direct	-	-
	Indirect	-	-
	<b>Total</b>	<b>-</b>	<b>-</b>

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Number Disposed</b>		<b>Shares</b>	<b>Options</b>
	Direct	-	-
	Indirect	-	5,654,762
	<b>Total</b>	<b>-</b>	<b>5,654,762</b>
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$0.042 per option.		
<b>No. of Securities Held After Change</b>		<b>Shares</b>	<b>Options</b>
	Direct	-	-
	Indirect	497,500	32,345,238
	<b>Total</b>	<b>497,500</b>	<b>32,345,238</b>
<b>Nature of Change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Off-Market Transfer		

**Part 2 – Change of Director's Interests in Contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of Contract</b>	
<b>Nature of Interest</b>	
<b>Name of Registered Holder (if issued securities)</b>	
<b>Date of Change</b>	
<b>No. and Class of Securities to Which Interest Related Prior to Change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest Acquired</b>	
<b>Interest Disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest After Change</b>	



The CFO Solution

19.08.2009

+ See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of Entity:</b>	PRIMA BIOMED LIMITED (ASX: PRR)
<b>ABN:</b>	90 009 237 889

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director:</b>	DR. RICHARD HAMMEL
<b>Date of Last Notice:</b>	11 August 2009

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or Indirect Interest</b>	Indirect		
<b>Nature of Indirect Interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Director Related Entity		
<b>Date of change</b>	12 August 2009		
<b>No. of securities held prior to change</b>		Shares	Options
	Direct	-	-
	Indirect	-	15,000,000
	<b>Total</b>	-	<b>15,000,000</b>
<b>Class</b>	Listed Options exercisable at \$0.02 on or before 31 December 2011 (PRRO)		
<b>Number Acquired</b>		Shares	Options
	Direct	-	-
	Indirect	-	-
	<b>Total</b>	-	-

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Number Disposed</b>		<b>Shares</b>	<b>Options</b>
	Direct	-	-
	Indirect	-	2,380,953
	<b>Total</b>	-	<b>2,380,953</b>
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$0.042 per option		
<b>No. of Securities Held After Change</b>		<b>Shares</b>	<b>Options</b>
	Direct	-	-
	Indirect	-	12,619,047
	<b>Total</b>	-	<b>12,619,047</b>
<b>Nature of Change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Off-Market Transfer		

**Part 2 – Change of Director's Interests in Contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of Contract</b>	
<b>Nature of Interest</b>	
<b>Name of Registered Holder (if issued securities)</b>	
<b>Date of Change</b>	
<b>No. and Class of Securities to Which Interest Related Prior to Change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest Acquired</b>	
<b>Interest Disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest After Change</b>	



19.08.2009

+ See chapter 19 for defined terms.